ABPI comment on Government's full response to the O'Shaughnessy Review
The ABPI has commented on the Government's full response to the O'Shaughnessy Review.
Janet Valentine, Executive Director of Innovation and Research Policy for ABPI, said:
"The ABPI has long called for a delivery-focussed approach to getting UK industry clinical trials back on track, and today the Government has delivered a clear plan that will make a real difference to patients.
“We’ve got a long way to go if we want to see sustained recovery, and achieve the ambition set out in Lord O’Shaughnessy’s review to quadruple recruitment to industry clinical trials. But by continuing to streamline approvals and set-up, and expanding dedicated capacity, we now have a clear strategy to rebuild global confidence in the UK’s clinical research offer.
“In an environment where there is ever-growing international competition for industry investment in research, today’s response is very welcome, and we will continue to play our part in putting it into action so that more patients can participate in trials and benefit from innovative therapies.”
- Clinical research
Last modified: 22 November 2023
Last reviewed: 22 November 2023